Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - Amarantus Bioscience Holdings, Inc. | ex10_1.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
___________________________________________________________________
Date of Report (Date of earliest event reported): October 7, 2011
Amarantus BioSciences, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
333-148922 |
26-0690857 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
675 Almanor Ave., Sunnyvale, CA |
94085 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (408) 737-2734
| ____________________________________________ (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 5 – Corporate Governance And Management
Item 5.03 Amendment to Articles of Incorporation or Bylaws
On October 7, 2011, a majority of our shareholders and our board of directors approved an amendment to Article 4, Section A of our Certificate of Incorporation to increase our total authorized common stock to 250,000,000 shares.
We filed a Certificate of Amendment with the Delaware Secretary of State to record the amendment. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
| Exhibit No. | Description |
| 3.1 | Certificate of Amendment |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: October 14, 2011 | Amarantus BioSciences, Inc. |
| By: /s/ Martin D. Cleary | |
| Martin D. Cleary | |
| Chief Executive Officer |
| 3 |